Loading candles…
Ind-Swift Laboratories Ltd, incorporated in 1995 and headquartered in Chandigarh, operates in the pharmaceutical and bulk drugs industries. The company specializes in pharmaceutical formulations, having exited its Active Pharmaceutical Ingredients (API) and Contract Research and Manufacturing Services (CRAMS) businesses by selling its API division to PI Industries in March 2024. Historically, Ind-Swift was recognized for its leadership in the Macrolide Antibiotic sector. In July 2025, the company concluded a merger with Ind-Swift Limited. Currently, it functions as a debt-free entity focusing exclusively on the global formulations market.
| INDSWFTLAB: The Board Meeting of the Company is scheduled to be held on August 11, 2025 to inter-alia, consider and approve Audited Financial Results for the… |
| 11 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve the Standalone & Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2025 | 30 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.